文献速递心脑血管急症

定量血流比值与血流储备分数指导冠状动脉血运重建(FAVOR III Europe):一项多中心、随机、非劣效性试验

Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
PubMed 文献 · Lancet · 2024-10-30
一句话结论在中间冠状动脉狭窄患者中,QFR指导策略12个月主要终点事件非劣于FFR未成立(差异2.5%,90%CI上限4.2%超过预设界值3.4%),作者认为FFR可用时不支持使用QFR。

FAVOR III Europe为多中心、随机、开放标签、非劣效性试验,在11个欧洲国家34个中心纳入2000例慢性冠脉综合征或稳定后的急性冠脉综合征、且至少有一处目测直径狭窄40-90%的中间非罪犯狭窄患者,1:1随机至QFR指导组(1008例)或FFR指导组(992例)。主要终点为12个月死亡、心肌梗死和计划外血运重建的复合终点。12个月时QFR组67例(6.7%)、FFR组41例(4.2%)发生主要终点事件(HR 1.63,95%CI 1.11-2.41),事件比例差异2.5%(90%双侧CI 0.9-4.2),90%CI上限超过预设非劣效界值3.4%,QFR未达到对FFR的非劣效性。作者结论认为,若FFR可用,该结果不支持使用QFR指导中间冠状动脉狭窄的血运重建决策,并可能对现行推荐QFR的临床指南产生影响。

要点

  • 12个月主要终点事件:QFR组67例(6.7%)vs FFR组41例(4.2%),HR 1.63(95%CI 1.11-2.41)。
  • 事件比例差异2.5%(90%双侧CI 0.9-4.2),90%CI上限4.2%超过预设非劣效界值3.4%,QFR未达到非劣效。
  • 两组各有18例(1.8%)发生操作相关不良事件,最常见为操作相关心肌梗死:QFR组10例(1.0%)vs FFR组7例(0.7%)。
  • QFR组有1例与索引操作相关的死亡。
  • 作者结论:若FFR可用,不支持使用QFR指导中间冠状动脉狭窄的血运重建决策。

适用人群与场景

  • 年龄18岁及以上、慢性冠脉综合征或稳定后的急性冠脉综合征、且至少有一处目测直径狭窄40-90%的中间非罪犯狭窄(研究病变)的患者。
  • 纳入场景为11个欧洲国家34个中心的侵入性冠状动脉造影评估。

诊断标准与关键阈值

  • 研究病变定义为目测估计直径狭窄40-90%的中间非罪犯狭窄。
  • 预设非劣效界值为3.4%。

研究设计与关键结果

  • 研究类型:多中心、随机、开放标签、非劣效性试验;34个中心、11个欧洲国家;2000例患者随机1:1至QFR指导组(1008例)或FFR指导组(992例)。
  • 基线:中位年龄67.3岁(IQR 59.9-74.7);男性1538例(76.9%),女性462例(23.1%);中位随访365天(IQR 365-365)。
  • 主要终点(12个月死亡、心肌梗死和计划外血运重建复合终点):QFR组67例(6.7%)vs FFR组41例(4.2%),HR 1.63(95%CI 1.11-2.41);事件比例差异2.5%(90%双侧CI 0.9-4.2),90%CI上限超过预设非劣效界值3.4%,QFR未达到对FFR的非劣效性。
  • 操作相关不良事件:两组各18例(1.8%);操作相关心肌梗死QFR组10例(1.0%)vs FFR组7例(0.7%);QFR组1例与索引操作相关的死亡。

证据类型、等级与局限

  • 证据类型:多中心、随机、开放标签、非劣效性试验(FAVOR III Europe)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:若FFR可用,该结果不支持使用QFR指导中间冠状动脉狭窄患者的血运重建决策。
  • 作者认为该发现可能对现行推荐QFR用于此目的的临床指南产生影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fractional flow reserve (FFR) or non-hyperaemic pressure ratios are recommended to assess functional relevance of intermediate coronary stenosis. Both diagnostic methods require the placement of a pressure wire in the coronary artery during invasive coronary angiography. Quantitative flow ratio (QFR) is an angiography-based computational method for the estimation of FFR that does not require the use of pressure wires. We aimed to investigate whether a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with an FFR-based strategy.

METHODS: FAVOR III Europe was a multicentre, randomised, open-label, non-inferiority trial comparing a QFR-based with an FFR-based diagnostic strategy for patients with intermediate coronary stenosis. Enrolment was performed in 34 centres across 11 European countries. Patients aged 18 years or older with either chronic coronary syndrome or stabilised acute coronary syndrome, and with at least one intermediate non-culprit stenosis (40-90% diameter stenosis by visual estimate; referred to here as a study lesion), were randomly assigned (1:1) to the QFR-guided or the FFR-guided group. Randomisation was done using a concealed web-based system and was stratified by diabetes and presence of a left anterior descending coronary artery study lesion. The primary endpoint was a composite of death, myocardial infarction, and unplanned revascularisation at 12 months. The predefined non-inferiority margin was 3·4% and the primary analysis was performed in the intention-to-treat population. The trial was registered with ClinicalTrials.gov (NCT03729739) and long-term follow-up is ongoing.

FINDINGS: Between Nov 6, 2018, and July 21, 2023, 2000 patients were enrolled and randomly assigned to the QFR-guided strategy (1008 patients) or the FFR-guided strategy (992 patients). The median age was 67·3 years (IQR 59·9-74·7); 1538 (76·9%) patients were male and 462 (23·1%) were female. Median follow-up time was 365 days (IQR 365-365). At 12 months, a primary endpoint event had occurred in 67 (6·7%) patients in the QFR group, and in 41 (4·2%) patients in the FFR group (hazard ratio 1·63 [95% CI 1·11-2·41]). The event proportion difference was 2·5% (90% two-sided CI 0·9-4·2). The upper limit of the 90% CI exceeded the prespecified non-inferiority margin of 3·4%. Therefore, QFR did not meet non-inferiority to FFR. A total of 18 (1·8%) patients in each group experienced an adverse procedural event, the most frequent being procedure-related myocardial infarction, which occurred in ten (1·0%) patients in the QFR group and seven (0·7%) in the FFR group. One patient in the QFR group died in relation to the index procedure.

INTERPRETATION: The results of the FAVOR III Europe trial do not support the use of QFR if FFR is available to guide revascularisation decisions in patients with intermediate coronary stenosis. This finding could have implications for current clinical guidelines recommending QFR for this purpose.

FUNDING: Medis Medical Imaging Systems and Aarhus University.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Andersen BK, Sejr-Hansen M, Maillard L, et al. Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial. Lancet. 2024. PMID: 39488224. doi:10.1016/S0140-6736(24)02175-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。